Quick Answer
Traws Pharma, Inc. reported Research And Development Expense of $11.43 million for the year ending 2023.
- Traws Pharma, Inc. showed an increase of +0.2% in Research And Development Expense from 2022 to 2023.
- This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2024.
- XBRL data for this metric is available from 2011 to 2023 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2011 to 2023), Traws Pharma, Inc.'s Research And Development Expense has declined by 49.5%.
- Historical annual values: Fiscal year 2023: $11.43 million | Fiscal year 2022: $11.41 million | Fiscal year 2021: $7.30 million | Fiscal year 2020: $16.90 million | Fiscal year 2019: $15.54 million | Fiscal year 2018: $16.92 million | Fiscal year 2017: $19.12 million | Fiscal year 2016: $20.07 million | Fiscal year 2015: $25.90 million | Fiscal year 2014: $49.43 million | Fiscal year 2013: $50.18 million | Fiscal year 2012: $52.76 million | Fiscal year 2011: $22.62 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: